Sinotau Pharmaceutical Group v. Navidea Biopharmaceuticals, Inc.

211 F. Supp. 3d 375, 2016 U.S. Dist. LEXIS 134602, 2016 WL 5660330
CourtDistrict Court, D. Massachusetts
DecidedSeptember 29, 2016
DocketCIVIL ACTION NO. 15-13254-RWZ
StatusPublished
Cited by6 cases

This text of 211 F. Supp. 3d 375 (Sinotau Pharmaceutical Group v. Navidea Biopharmaceuticals, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Sinotau Pharmaceutical Group v. Navidea Biopharmaceuticals, Inc., 211 F. Supp. 3d 375, 2016 U.S. Dist. LEXIS 134602, 2016 WL 5660330 (D. Mass. 2016).

Opinion

MEMORANDUM OF DECISION

ZOBEL, SENIOR UNITED STATES DISTRICT JUDGE

In 2015, Sinotau Pharmaceutical Group (“Sinotau”) and Navidea Biopharmaceuti-cals, Inc. (“Navidea”), executed a Binding Term Sheet involving an exclusive license to NAV4694, a pharmaceutical imaging agent. In this lawsuit, Sinotau alleges that Navidea breached its contractual obligations to Sinotau by refusing to abide by the parties’ agreement (Counts I and II) and that Navidea tortiously interfered with Sinotau’s advantageous prospective business relationships (Count III). Sinotau also brings alternative claims of promissory es-toppel, breach of the implied covenant of good faith, and failure to use best efforts (Counts IV, V, and VI). Navidea has moved to dismiss all claims. See Docket #17.

I. Factual Background

These facts are alleged in the plaintiffs amended complaint (Docket # 16). See Ocasio-Hernández v. Fortuño-Burset, 640 F.3d 1, 5 (1st Cir.2011).

Navidea holds an exclusive license that covers patent rights to NAV4694, a pharmaceutical imaging agent owned or controlled by AstraZeneca AB (“AZ”). Under an agreement entered into by Navidea’s predecessor (the “Navidea-AZ License Agreement”), Navidea owns the transfer-rable right to manufacture, develop, and commercialize NAV4694. Between the end of 2014 and the beginning of 2015, Navidea approached Sinotau about assuming Navi-dea’s worldwide license of NAV4694. In early 2015, Sinotau and Navidea began negotiating terms of the anticipated NAV4694 worldwide license agreement.

In March 2015, the parties signed a “Binding Term Sheet for Exclusive License” (“Binding Term Sheet”), under which Navidea agreed to grant Sinotau an exclusive license to NAV4694 subject to the “re-negotiation of the Navidea-AZ License Agreement to include economic terms acceptable to [Sinotau] as specified in the ‘Updated Proposal for Worldwide Licensing of NAV4694’ forwarded by [Si-notau] to [Navidea] on March 4, 2015.” Docket # 16 ¶ 68 (alterations in original) (quoting the Binding Term Sheet).

After signing the Binding Term Sheet, Sinotau and Navidea exchanged draft licensing agreements. During this time, Na-videa tried to renegotiate the material terms in the Binding Term Sheet. Sinotau claims that it “entertained Navidea’s proposed modifications” but that the “parties never reached final agreement as to a proposed modification to the Binding Term Sheet.” Docket # 16 ¶¶ 116, 119. Sinotau sent Navidea an exclusive license agreement on June 23, 2015, that included material terms from the Binding Term Sheet as well as additional terms and conditions Navidea had proposed. Navidea did not sign this license agreement nor any other exclusive license agreement with Sinotau. Sinotau alleges several reasons why Navi-dea “wanted to back away from the deal it had struck,” including that it had “entertained at least one proposal from a Sinotau [378]*378competitor that surpassed the economic terms set forth in the Binding Term Sheet” and that clinical results for a related drug increased NAV4694’s perceived value. Docket # 16 ¶¶ 109-111.

In August 2015, Sinotau filed the present suit, and in October 2015, it amended its complaint. Navidea now moves to dismiss the amended complaint.

II. Legal Standard

“To survive a motion to dismiss, a complaint must contain sufficient factual matter, accepted as true, to ‘state a claim to relief that is plausible on its face.’ ” Ashcroft v. Iqbal, 556 U.S. 662, 678, 129 S.Ct. 1937, 173 L.Ed.2d 868 (2009) (quoting Bell Atl. Corp. v. Twombly, 550 U.S. 544, 570, 127 S.Ct. 1955, 167 L.Ed.2d 929 (2007)). “A claim has facial plausibility when the plaintiff pleads factual content that allows the court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Id.

For purposes of a motion to dismiss, the court accepts all well-pleaded factual allegations as true and draws all reasonable inferences in the plaintiffs favor. See Rodríguez-Reyes v. Molina-Rodríguez, 711 F.3d 49, 52-53 (1st Cir.2013). In addition to facts and documents included in or incorporated into the complaint, the court “may also consider ‘documents incorporated by reference in [the complaint], matters of public record, and other matters susceptible to judicial notice.’” Giragosian v. Ryan, 547 F.3d 59, 65 (1st Cir.2008) (alteration in original) (quoting In re Colonial Mortg. Bankers Corp., 324 F.3d 12, 20 (1st Cir.2003)).

III. Analysis

A. Choice of Law

The parties disagree whether Massachusetts or Delaware law should apply to Sinotau’s contract and tort claims. Federal courts sitting in diversity, as here, apply state substantive law. See Crellin Techs., Inc. v. Equipmentlease Corp., 18 F.3d 1, 4 (1st Cir.1994) (citing Erie R.R. Co. v. Tompkins, 304 U.S. 64, 78, 58 S.Ct. 817, 82 L.Ed. 1188 (1938)). “In determining what state law pertains, the court must employ the choice-of-law framework of the forum state,” here, Massachusetts. Id.

“The first step in a choice of law analysis is to determine whether an actual conflict exists between the substantive laws of the interested jurisdictions,” in this case, Massachusetts and Delaware. Reicher v. Berkshire Life Ins. Co. of Am., 360 F.3d 1, 4 (1st Cir.2004). Because, as explained below, the outcome of the present motion is the same under Massachusetts and Delaware law, I need not resolve which state’s law applies to each of Sino-tau’s claims.

B. Counts I and II—Breach of Contract

In Counts I and II, Sinotau alleges that Navidea breached the parties’ contract by failing “to grant an exclusive license to Sinotau subject to the material terms contemplated by the Binding Term Sheet despite its promise to do so.” Docket # 16 ¶ 147. In Count I, Sinotau seeks damages, and in Count II, an order of specific performance requiring that Navidea grant it the worldwide license to NAV4694. Navi-dea raises three defenses to these counts: (1) that the Binding Term Sheet did not constitute a valid contract; (2) that the parties did not intend to be bound by the Binding Term Sheet’s licensing provisions; and (3) that there was no breach as a matter of law because the Binding Term Sheet’s condition precedent was not satisfied. These arguments are insufficient to defeat Sinotau’s breach of contract claims [379]*379on a motion to dismiss under both Massachusetts and Delaware law.

First, Sinotau has adequately pled that the Binding Term Sheet created a valid contract. “[T]o create an enforceable contract, there must be agreement between the parties on the material terms of that contract, and the parties must have a present intention to be bound by that agreement.” Situation Mgmt.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
211 F. Supp. 3d 375, 2016 U.S. Dist. LEXIS 134602, 2016 WL 5660330, Counsel Stack Legal Research, https://law.counselstack.com/opinion/sinotau-pharmaceutical-group-v-navidea-biopharmaceuticals-inc-mad-2016.